The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Crizotinib in ROS1-rearranged lung cancer (EUCROSS): Updated overall survival.
 
Sebastian Yves Friedrich Michels
Honoraria - AstraZeneca; Janssen Oncology; Merck KGaA; Novartis; Pfizer; Takeda
Consulting or Advisory Role - Boehringer Ingelheim; Pfizer; Roche Pharma AG
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Novartis
 
Jeremy Franklin
No Relationships to Disclose
 
Bartomeu Massuti
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Merck Serono; Roche; Takeda
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Roche
Travel, Accommodations, Expenses - Roche
 
Martin Sebastian
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen Oncology; Lilly; MSD; Novartis; Pfizer/EMD Serono; Roche/Genentech; Sanofi; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen Oncology; Lilly; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi; Takeda
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - Pfizer; Takeda
 
Enriqueta Felip
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi Sankyo Europe GmbH; GlaxoSmithKline; Janssen; Lilly; Merck Serono; MSD Oncology; Novartis; Peptomyc; Pfizer; Roche; Sanofi; Takeda
Speakers' Bureau - AstraZeneca; Bristol Myers Squibb; CME outfitters; Lilly; Medscape; Merck Sharp & Dohme; PeerVoice; Pfizer; Roche; Takeda
Research Funding - Merck (Inst); Merck KGaA (Inst)
Other Relationship - GRÍFOLS
 
Christian Grohé
No Relationships to Disclose
 
Delvys Rodriguez-Abreu
Consulting or Advisory Role - AstraZeneca Spain; Bristol-Myers Squibb; MSD; Novartis; Roche
Speakers' Bureau - Bristol-Myers Squibb; MSD; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Roche
 
Helge Bischoff
No Relationships to Disclose
 
Enric Carcereny
No Relationships to Disclose
 
Jesús Corral
No Relationships to Disclose
 
Amelia Insa
No Relationships to Disclose
 
Martin Reck
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Samsung Bioepis; Sanofi/Regeneron
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Sanofi/Aventis
 
Sacha Rothschild
Honoraria - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Roche Pharma AG (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche Pharma AG (Inst); Takeda (Inst)
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Merck Serono (Inst)
Travel, Accommodations, Expenses - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Roche Pharma AG (Inst); Takeda (Inst)
Other Relationship - Federal Drug Commission of the Swiss Federal Office of Public Health
 
Mariano Provencio
No Relationships to Disclose
 
Matthias Scheffler
No Relationships to Disclose
 
Martin Hellmich
No Relationships to Disclose
 
Lucia Nogova
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Janssen; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Novartis; Pfizer; Roche; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Dracen (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Celgene; Janssen; Novartis; Pfizer
 
Reinhard Büttner
Research Funding - Pfizer (Inst)
 
Rafael Rosell
Consulting or Advisory Role - Blueprint Medicines; Merck KGaA
 
Juergen Wolf
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma Europe; Daiichi Sankyo Europe GmbH; Ignyta; Janssen; Lilly; Loxo; Loxo/Lilly; MSD; Novartis; Pfizer; Roche; Seagen; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Amgen; AstraZeneca; Bayer; Blueprint Medicines; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo Europe GmbH; Ignyta; Janssen; Lilly; Loxo/Lilly; MSD Oncology; Novartis; Pfizer; Roche; Seagen; Takeda
Research Funding - Bristol-Myers Squibb; Janssen; Novartis; Pfizer